Alle Studien
Aktiv, aber nicht rekrutierendPHASE2, PHASE3INTERVENTIONELL

Eine Studie zur Bewertung der Wirksamkeit und Sicherheit von Mitapivat (AG-348) bei Teilnehmern mit Sichelzellenanämie (RISE UP)

This study, called RISE UP, is testing a new medicine called mitapivat for people with sickle cell disease. It has two main goals: first, to find the best dose of mitapivat, and second, to see how well it works and if it's safe. Specifically, researchers want to know if mitapivat can help increase the amount of a healthy red blood cell chemical (hemoglobin) in the blood and reduce painful episodes called sickle cell crises. Over time, the study will also look at the longer-term effects of this medicine. If you have sickle cell disease, this study could be an opportunity to explore a potential new treatment.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2, PHASE3
Sponsor
Agios Pharmaceuticals, Inc.
Einschreibeziel
286
Starten
11. Feb. 2022
Geschätzte Fertigstellung
01 Feb 2030

Worum geht es in dieser Studie?

Sickle cell disease is a lifelong condition that affects your red blood cells. Normally, these cells are round and flexible, carrying oxygen around your body. But with sickle cell disease, they can become stiff and C-shaped, like a farm tool called a sickle. These 'sickled' cells can block blood flow, leading to severe pain, called sickle cell crises, and other health problems.

This study is investigating a new medicine called mitapivat. It's designed to help your blood cells work better. The researchers want to find out the best amount of mitapivat to give and how well it helps people with sickle cell disease. They will be looking to see if it can increase healthy red blood cells and reduce the number of painful crises you might experience. It's important to remember that this is a research study, and we're still learning about this medicine.

The study is split into two main parts, called Phase 2 and Phase 3. The first part helps find the right dose. Then, a larger group of people will take part in Phase 3 to get a clearer picture of how effective and safe mitapivat is compared to a dummy pill (placebo). After these main parts, there's an option to continue taking mitapivat for a longer period to see its long-term effects.

Wichtige Erkenntnisse

  • This study is testing a new medicine called mitapivat for sickle cell disease.
  • It aims to find the right dose and see if it helps increase red blood cells and reduce painful crises.
  • The study involves taking either mitapivat or a dummy pill (placebo).
  • Participation includes regular clinic visits and health checks.
  • Potential benefits might include access to a new treatment, but there are also potential side effects.
  • You can leave the study at any time without affecting your normal care.

Wer könnte berechtigt sein?

To join this study, you need to be at least 16 years old. (In France and Germany, you must be 18 or older). If you're 16 or 17, you must have finished puberty. You need to have a clear diagnosis of sickle cell disease, including common types like HbSS or HbSC.

Over the past year, you should have experienced at least two, but no more than ten, painful sickle cell crises. Your haemoglobin level (a measure of your red blood cells) needs to be within a specific range. If you're currently taking a medicine called hydroxyurea, your dose must have been stable for at least 3 months. Women who could become pregnant must agree to use two types of birth control during the study.

There are also some reasons you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you regularly receive blood transfusions. You would also be excluded if you have certain severe liver or kidney problems, or if you've had a stem cell transplant or gene therapy. Also, if you're taking certain other ongoing sickle cell medicines or investigational treatments, you might not be eligible.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you 16 years or older? (18+ in France/Germany)
  2. Do you have a diagnosis of sickle cell disease?
  3. Have you had 2 to 10 painful sickle cell crises in the last year?
  4. Are you able to use two forms of contraception if you could become pregnant?
  5. Sind Sie NICHT schwanger oder stillen?
  6. Are you NOT regularly having blood transfusions?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will involve several visits to a clinic. You'll be given either mitapivat or a dummy pill (placebo) to take. Initially, the study will involve different doses of mitapivat being tested in smaller groups. Then, in the main part, you'll either take the recommended dose of mitapivat or a placebo for about 52 weeks (roughly a year). This will be decided by chance, like flipping a coin. You won't know if you're getting the active medicine or the placebo, and neither will your local study doctor.

Throughout the study, you'll have regular checks, which might include blood tests, physical exams, and discussions about how you're feeling and any symptoms you have. The study team will explain all the procedures in detail. After the main part of the study, you might have the option to continue taking mitapivat for up to 216 weeks (over 4 years) in an open-label part, meaning everyone in this part would receive mitapivat.

Potenzielle Risiken und Vorteile

Taking part in a study like this might offer some potential benefits, such as access to a new medicine that could improve your red blood cells and reduce pain, under close medical supervision. However, there are also potential risks; mitapivat might cause side effects, some of which we may not fully know yet. These will be explained to you in detail by the study team. You always have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Standorte (91)

  • Universität von Kalifornien San Diego
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten
  • UCLA Health
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Children's Hospital Oakland
    Verifizierte Postleitzahl
    Oakland, Vereinigte Staaten
  • University of Connecticut Health Center
    Verifizierte Postleitzahl
    Farmington, United States
  • Nationales Kinderkrankenhaus
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • MedStar Washington Hospital Center
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • Sylvester Comprehensive Cancer Center-Miami
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten
  • University of Chicago Medical Center
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten
  • Riley Hospital For Children
    Verifizierte Postleitzahl
    Indianapolis, Vereinigte Staaten
  • LSU Health Sciences Center - Shreveport
    Verifizierte Postleitzahl
    Shreveport, United States
  • National Heart Lung and Blood Institute
    Verifizierte Postleitzahl
    Bethesda, Vereinigte Staaten
  • Kaiser Permanente - Largo Medical Center
    Verifizierte Postleitzahl
    Largo, United States

Häufige Fragen

Was ist Sichelzellenanämie?

It's a blood condition where red blood cells become stiff and C-shaped, causing pain and other health issues.

What is mitapivat?

It's a new medicine being tested to help make red blood cells healthier and reduce pain crises in people with sickle cell disease.

Was ist ein Placebo?

A placebo is a dummy pill that looks like the real medicine but contains no active ingredients. It helps researchers see if the real medicine is truly effective.

How long would I need to be in the study?

The main part of the study lasts about a year, with an option to continue for several more years afterwards.

Can I still take my regular medicines?

You might be able to, but some medicines need to be stopped or stable for a certain time before joining. The study team will tell you which ones.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.